Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.
ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.
Z-1018, which combines a glycoprotein E (gE) antigen and proprietary adjuvant, was evaluated in adults aged 50 to 69 and the 100 µg dose will advance to part 2 of the trial.
In its updated guidelines, the AAP recommends that all children aged 6 to 23 months be vaccinated against COVID-19, citing the population's high risk for severe infection.